Group 1: Santander's Sale and Partnership - Santander is selling approximately 49% of Santander Polska's share capital and 50% of its Polish asset management business to Erste Group for $7.9 billion [1][2] - The deal includes a partnership where Santander will provide Erste access to its payment system, allowing both banks to explore opportunities in payments, particularly with Santander Polska post-completion [1][2] Group 2: Corporate and Investment Banking Collaboration - Santander and Erste are forming a corporate and investment banking partnership to leverage each other's regional strengths, offering local solutions and market insights to corporate and institutional clients through a referral model [3] - This partnership aims to facilitate seamless client interactions and service offerings [3] Group 3: Economic Outlook and Strategic Focus - Santander's Executive Chair, Ana Botín, highlighted the bank's focus on helping clients manage volatility related to U.S. tariffs and geopolitical uncertainty, which has contributed to a decline in the five-year growth forecast for the world economy to 3.1%, the lowest in 16 years [4] - The bank is leveraging its global scale and diversification as stabilizers in the current economic environment, anticipating continued profitability growth by 2025 [5] Group 4: Importance of Real-Time Payments - Research indicates that offering real-time payments is crucial for banks to attract and retain small and medium-sized business (SMB) clients, with many SMBs willing to pay fees for instant payment advantages [6][7] - Specifically, 88% of the smallest SMBs, those with annual revenues of less than $100,000, would be willing to pay a percentage fee for instant payments [7]

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,452,461,656Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry under nu ...

After underperforming for so long, it is nice to see Banco Santander, S.A. ( NYSE: SAN ) doing much better these days. Even by the standards of European financials, this bank has been an exceptional performer so far this year, returning over 60% in dollarI like to take a long term, buy-and-hold approach to investing, with a bias toward stocks that can sustainably post high quality earnings. Mostly found in the dividend and income section. Blog about various US/Canadian stocks at 'The Compound Investor', and ...

Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025Board composition: renewal of four Directors and ratification of the cooptation of Jean-Paul Kress Paris, April 30, 2025. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2025, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders. The Genera ...

Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy. Sanofi announces today the closing of the sale to CD&R of a 50.0% controlling stake of its consumer healthcare business Opella. Sanofi retains a significant shareholding of Opella with a 48.2% stake. Bpifrance will own a 1.8% stake in Opella and will join the Board. The transaction was ...

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April, 2025 Commission File Number: 001-12518 Banco Santander, S.A. (Exact name of registrant as specified in its charter) Ciudad Grupo Santander 28660 Boadilla del Monte (Madrid) Spain (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F ...

Thomas Triomphe Executive Vice President, Vaccines, Sanofi, says: "Le Mans is the ultimate race against time — just like our fight against meningitis. At Sanofi, we believe science is our engine, partnerships our fuel, and awareness our finish line. By bringing the Meningitis Flag to the world stage, we're not just backing a car — we're supporting a movement. Because when every second counts, we choose to race for lives." Louise McEwen Chief Marketing Officer, McLaren Racing, adds: "We're proud to be workin ...

Core Insights - The company reported a Q1 sales growth of 9.7% at constant exchange rates (CER) and a business EPS of €1.79, indicating a strong start to 2025 [1][3][8] Sales Performance - Pharma launches generated sales of €0.8 billion, reflecting a 43.8% increase, primarily driven by ALTUVIIIO [6] - Dupixent sales reached €3.5 billion, up 20.3%, while vaccine sales amounted to €1.3 billion, up 11.4% due to favorable phasing of Beyfortus [6] - Total IFRS net sales were reported at €9,895 million, representing a 10.8% increase [8] Financial Metrics - Business EPS increased by 17.0% reported and 15.7% at CER, reaching €1.79 [6][8] - IFRS net income rose by 65.2% to €1,872 million, with IFRS EPS reported at €1.52, up 67.0% [8] - Free cash flow was reported at €1,029 million [8] Pipeline and Approvals - The company achieved six regulatory approvals across various therapeutic areas, including immunology, rare diseases, and oncology [6][5] - Significant progress was noted in the pipeline, with new data from mid-stage studies unlocking late-stage studies in asthma and skin diseases [6][5] Capital Allocation and Strategy - The company confirmed its capital allocation strategy, including a share buyback program of €5 billion, with 72% already repurchased [7][4] - The anticipated closing of the sale of a controlling stake in Opella is expected in Q2 [7] Future Outlook - Sales are projected to grow by a mid-to-high single-digit percentage at CER in 2025, with business EPS expected to increase at a low double-digit percentage at CER before share buyback [7]

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placeboIn the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatmentCSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved Paris and Tarrytown, NY, April 18, 2 ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig now targeting chronic rhinosinusitis and COPD in addition to asthmaItepekimab expanding into chronic rhinosinusitis along with COPD and bronchiectasis; phase 3 readouts in COPD in H2 2025 and bronchiectasis in 2026 Paris, April 15, 2025. Sanofi today shared new progress from its mid- to late-stage respiratory ...